CRBP— Corbus Pharmaceuticals Holdings, Inc.

MaterialsBiotechnology$197M mkt cap

Metric	FY2023	FY2022	FY2021	FY2020
Research and development	$31.2M+93.1%	$16.1M-55.7%	$36.4M-62.9%	$98.3M
General and administrative	$13.9M-25.6%	$18.7M-8.5%	$20.4M-28.3%	$28.5M
Litigation settlement	$0-100.0%	$5.0M	$0	—
Total operating expenses	$45.1M+13.2%	$39.8M-30.0%	$56.9M-55.1%	$126.7M
Operating loss	-$45.1M-13.2%	-$39.8M+28.9%	-$56.0M+54.4%	-$122.8M
Other income (expense), net	$3.4M+7049.4%	-$49K-100.4%	$11.9M-10.3%	$13.3M
Interest income (expense), net	-$2.9M-37.1%	-$2.1M-16.5%	-$1.8M-78.0%	-$1.0M
Change in fair value of derivative liability	-$3K-102.7%	$97K-85.4%	$663K+364.3%	-$251K
Foreign currency transaction gain (loss), net	$11K+102.6%	-$427K-11.3%	-$384K+14.6%	-$450K
Other income (expense), net	$474K+118.9%	-$2.5M-124.3%	$10.3M-10.3%	$11.5M
Net loss	-$44.6M-5.3%	-$42.3M+7.2%	-$45.6M+59.0%	-$111.3M
Net loss per share, basic	-$10.31-1.6%	-$10.15+9.0%	-$11.15	—
Net loss per share, diluted	-$10.31-1.6%	-$10.15+9.0%	-$11.15	—
Weighted average number of common shares outstanding, basic	4.3M+3.8%	4.2M+1.8%	4.1M	—
Weighted average number of common shares outstanding, diluted	4.3M+3.8%	4.2M+1.8%	4.1M	—
Net Income (Loss)	-$44.6M-5.3%	-$42.3M+7.2%	-$45.6M+59.0%	-$111.3M
Change in unrealized gain (loss) on marketable debt securities	$125K+295.7%	-$64K-1.9%	-$62K	—
Total other comprehensive income (loss)	$125K+295.7%	-$64K-1.9%	-$62K	—
Total comprehensive loss	-$44.5M-4.9%	-$42.4M+7.2%	-$45.7M+58.9%	-$111.3M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.